DiagnaMed Announces BRAIN AGE Trademark Registration Approved by CIPO

BRAIN AGE solution is part of the CERVAI Brain Health AI Platform

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), an artificial intelligence digital healthcare company, announced its application for registration for trademark on its BRAIN AGE brand has been approved by the Canadian Intellectual Property Office (CIPO), particularly for commercial use throughout Canada for the goods and services for which it is registered as a neurological monitoring apparatus, electroencephalogram-based apparatus, and brain monitoring apparatus.

The Company continues to expand its commercial initiatives in Canada for its CERVAI Brain Health AI Platform, which includes the BRAIN AGE estimation solution, and is part of the Hamilton Ecosystem to Accelerate and Leverage Trials of Health Innovation (HEALTHI) program in assisting the Company in developing relationships with world-class clinicians and hospital facilities in Canada’s leading research hospitals, such as Hamilton Health Sciences and St. Joe’s Healthcare Hamilton.

The CERVAI Brain Health commercial pilot program is available to clinics in Canada and the U.S. Ideal clinics for the pilot program must focus on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical research for neurological and cognitive disorders. For more information about CERVAI and joining the pilot program, visit https://www.diagnamed.com/hcpartner.

CERVAI Brain Health AI Platform is a world-first consumer brain health and wellness AI solution that estimates BRAIN AGE and provides a brain health score. Based on research and development at Drexel University and the University of Miami, CERVAI combines a BRAIN AGE Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues. CERVAI can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram (“EEG”) headset and calculating the data with a proprietary machine-learning model. In addition, CERVAI can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help to decrease the development or progression of cognitive decline.